WESTMINSTER, Colo., Oct. 17, 2023 /PRNewswire/ -- Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone repair, today announced long-term follow-up data from its pivotal IDE study of i-FACTOR Peptide-Enhanced Bone Graft. Published data demonstrated fusion rates in single-level Anterior Cervical Discectomy and Fusion (ACDF) of 98.6% after six years in patients treated with i-FACTOR and reinforces Cerapedics' commitment to capturing long-term clinical evidence. In particular, the results further support the safety and efficacy profile of i-FACTOR at one and two years, as published in Spine and Neurosurgery. . i-FACTOR has proven statistical superiority vs

WESTMINSTER, Colo., July 19, 2023 /PRNewswire/ -- Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone repair, announced today it is expanding its headquarters in the Denver metro area to support the growth of its products, which include the U.S. Food and Drug Administration (FDA)-approved i-FACTOR® bone graft for cervical spinal fusion and its next-generation product currently being evaluated for lumbar spinal fusion."Since the launch of i-FACTOR, we have seen a continuous increase in its use in spinal fusion. We are committed to supporting the needs of surgeons and their patients by expanding our facility," said Valeska Schroeder, Chief Executive Officer of Cerapedics. "We are fortunate to be based in Colorado and to recruit from the area's experienced, innovation-focused talent pool as we prepare to launch our next-generation product."i-FACTOR is the only spinal bone graft powered by P-15 Osteogenic Cell Binding Peptide™, and it is just one of two FDA approved Class III drug-device bone grafts with a spinal indication. i-FACTOR has proven statistical superiority vs. local autograft in overall success (defined as meeting Fusion, Function (Neck Disability Index), Neurological and Safety endpoints) at one and two-year endpoints for single-level Anterior Cervical Discectomy and Fusion.Cerapedics has fully enrolled its 290-patient randomized controlled clinical study evaluating the safety and efficacy of the next-generation P-15 Peptide Enhanced Bone Graft in transforaminal lumbar interbody fusion (TLIF) surgery

Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone repair, announced today it is expanding its headquarters in the Denver metro area to support the growth of its products, which include the U.S. Food and Drug Administration (FDA)-approved i-FACTOR® bone graft for cervical spinal fusion and its next-generation product currently being evaluated for lumbar spinal fusion.